[go: up one dir, main page]

WO1996023071A3 - ANTICORPS MONOCLONAUX SPECIFIQUES DE DIFFERENTS EPITOPES DE gp39 HUMAINE ET PROCEDES CONCERNANT LEUR UTILISATION A DES FINS DE DIAGNOSTIC ET DE THERAPIE - Google Patents

ANTICORPS MONOCLONAUX SPECIFIQUES DE DIFFERENTS EPITOPES DE gp39 HUMAINE ET PROCEDES CONCERNANT LEUR UTILISATION A DES FINS DE DIAGNOSTIC ET DE THERAPIE Download PDF

Info

Publication number
WO1996023071A3
WO1996023071A3 PCT/US1996/001119 US9601119W WO9623071A3 WO 1996023071 A3 WO1996023071 A3 WO 1996023071A3 US 9601119 W US9601119 W US 9601119W WO 9623071 A3 WO9623071 A3 WO 9623071A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
bind
monoclonal antibodies
epitopes
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1996/001119
Other languages
English (en)
Other versions
WO1996023071A2 (fr
WO1996023071A9 (fr
Inventor
Anthony W Siadak
Diane Hollenbaugh
Lisa K Gilliland
Marcia L Gordon
Jurgen Bajorath
Alejandro A Aruffo
Linda J Harris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IL11688296A priority Critical patent/IL116882A/en
Priority to MX9705610A priority patent/MX9705610A/es
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Priority to AU49669/96A priority patent/AU692074B2/en
Priority to EP96906207A priority patent/EP0807175A2/fr
Priority to CZ972339A priority patent/CZ233997A3/cs
Priority to NZ303375A priority patent/NZ303375A/xx
Priority to PL96323565A priority patent/PL182868B1/pl
Priority to JP8523029A priority patent/JPH10513348A/ja
Publication of WO1996023071A2 publication Critical patent/WO1996023071A2/fr
Publication of WO1996023071A3 publication Critical patent/WO1996023071A3/fr
Publication of WO1996023071A9 publication Critical patent/WO1996023071A9/fr
Priority to NO973447A priority patent/NO973447L/no
Priority to FI973120A priority patent/FI973120A7/fi
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des anticorps monoclonaux, des fragments de liaison à l'antigène (Fab) et des protéines de liaison recombinantes spécifiques de gp39 humaine. Ces anticorps sont spécifiques d'au moins 12 épitopes différents de gp39. L'invention concerne également des hybridomes sécrétant des anticorps spécifiques se liant à ces épitopes. L'invention concerne aussi la séquence d'acides aminés des régions variables à chaînes légères et lourdes d'immunoglobuline, lesquelles régions variables se lient aux épitopes de gp39 et fournissent le sFv et les anticorps humanisés de liaison de gp39. L'invention concerne enfin des compositions pharmaceutiques comprenant les anticorps monoclonaux, les fragments de liaison à l'antigène (Fab) et les protéines de liaison recombinantes qui se lient à la gp39, ainsi que des procédés d'utilisation de ces compositions pour le diagnostic d'états pathologiques, l'inhibition de l'activation des lymphocytes B et le traitement de troubles immunologiques tels que les maladies auto-immunes, les réactions allergiques, le rejet d'organe et les réactions du greffon contre l'hôte. Les anticorps de la présente invention peuvent également s'utiliser pour l'imagerie des cellules qui expriment la gp39 sur leur surface, et notamment les cellules tumorales telles que les lymphomes, et pour cibler des agents thérapeutiques par rapport à des cellules cibles.
PCT/US1996/001119 1995-01-26 1996-01-26 ANTICORPS MONOCLONAUX SPECIFIQUES DE DIFFERENTS EPITOPES DE gp39 HUMAINE ET PROCEDES CONCERNANT LEUR UTILISATION A DES FINS DE DIAGNOSTIC ET DE THERAPIE Ceased WO1996023071A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
IL11688296A IL116882A (en) 1995-01-26 1996-01-24 Monoclonal antibodies specific for different epitopes of human gp39 and methods for their use in diagnosis and therapy
PL96323565A PL182868B1 (pl) 1995-01-26 1996-01-26 Przeciwciała monoklonalne specyficzne dla różnych epitopów ludzkiego gp39 oraz sposoby ich stosowania w diagnozie i terapii
AU49669/96A AU692074B2 (en) 1995-01-26 1996-01-26 Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
EP96906207A EP0807175A2 (fr) 1995-01-26 1996-01-26 ANTICORPS MONOCLONAUX SPECIFIQUES DE DIFFERENTS EPITOPES DE gp39 HUMAINE ET PROCEDES CONCERNANT LEUR UTILISATION A DES FINS DE DIAGNOSTIC ET DE THERAPIE
CZ972339A CZ233997A3 (en) 1995-01-26 1996-01-26 MONOCLONAL ANTIBODIES AGAINST VARIOUS EPITOPES OF HUMAN pg39 AND METHODS OF THEIR USE IN DIAGNOSIS AND THERAPY
NZ303375A NZ303375A (en) 1995-01-26 1996-01-26 Monoclonal antibodies specific for different epitopes of human gp39 and diagnostic and therapeutic methods using them
JP8523029A JPH10513348A (ja) 1995-01-26 1996-01-26 ヒトｇｐ３９の種々のエピトープに対して特異的なモノクローナル抗体およびその診断および治療における使用
MX9705610A MX9705610A (es) 1995-01-26 1996-01-26 Anticuerpos monoclonales especificos para diferentes epitopos de la gp39 humana y metodos para su uso en diagnostico y terapia.
FI973120A FI973120A7 (fi) 1995-01-26 1997-07-25 Ihmisen gp39:n eri epitoopeille spesifisiä monoklonaalisia vasta-aineita ja menetelmiä niiden käyttämiseksi diagnosoinnissa ja terapiassa
NO973447A NO973447L (no) 1995-01-26 1997-07-25 Monoklonale antistoffer som er spesifikke for forskjellige epitoper i human-gp 39, og fremgangsmåter for deres anvendelse i diagnose og terapi

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/379,057 US5876950A (en) 1995-01-26 1995-01-26 Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US08/379,057 1995-01-26

Publications (3)

Publication Number Publication Date
WO1996023071A2 WO1996023071A2 (fr) 1996-08-01
WO1996023071A3 true WO1996023071A3 (fr) 1996-09-26
WO1996023071A9 WO1996023071A9 (fr) 1996-11-28

Family

ID=23495642

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/001119 Ceased WO1996023071A2 (fr) 1995-01-26 1996-01-26 ANTICORPS MONOCLONAUX SPECIFIQUES DE DIFFERENTS EPITOPES DE gp39 HUMAINE ET PROCEDES CONCERNANT LEUR UTILISATION A DES FINS DE DIAGNOSTIC ET DE THERAPIE

Country Status (15)

Country Link
US (1) US5876950A (fr)
EP (2) EP1728864B1 (fr)
JP (1) JPH10513348A (fr)
AU (1) AU692074B2 (fr)
CA (1) CA2210419A1 (fr)
CZ (1) CZ233997A3 (fr)
ES (1) ES2391101T3 (fr)
FI (1) FI973120A7 (fr)
HU (1) HUP9802401A3 (fr)
IL (1) IL116882A (fr)
MX (1) MX9705610A (fr)
NO (1) NO973447L (fr)
NZ (1) NZ303375A (fr)
PL (1) PL182868B1 (fr)
WO (1) WO1996023071A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US9399680B2 (en) 2007-12-05 2016-07-26 Chugai Seiyaku Kabushiki Kaisha Nucleic acids encoding anti-NR10 antibodies

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405270B2 (en) * 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5961974A (en) 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
CA2089229C (fr) 1992-02-14 2010-04-13 Alejandro A. Aruffo Recepteur cd40cr et ligands pour celui-ci
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
AU710998B2 (en) * 1996-03-20 1999-10-07 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4 /CD28/B7 pathways and compositions for use therewith
WO1998030241A1 (fr) * 1997-01-10 1998-07-16 Biogen, Inc. Procedes d'administration therapeutique de composes anti-cd40l
EA200501076A1 (ru) * 1997-01-10 2006-06-30 Байоджен Айдек Ма Инк. Лечение волчаночного нефрита с использованием анти-cd40l соединений
EP1754490A3 (fr) 1997-06-20 2010-01-20 Biogen Idec MA Inc. Thérapie de blocage par CD154 pour transplantation de tissus d'ilots pancréatiques chez les primates
EP1005372B1 (fr) * 1997-06-20 2002-01-02 Tanox Pharma B.V. Immunotoxines anti-cd40l servant a traiter des maladies
AU8266798A (en) * 1997-06-27 1999-01-19 Biogen, Inc. Cd154 blockade therapy for autoimmune diseases
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
HUP0101689A3 (en) * 1998-04-03 2004-08-30 Trustees Of Darmouth College H Use of anti-gp39 antibodies for treatment and/or reversal of lupus and associated kidney disease
CA2345903C (fr) * 1998-10-16 2006-09-26 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Pathogenicide moleculaire induisant une resistance a la maladie chez des vegetaux
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US7192698B1 (en) * 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
FR2798386B1 (fr) 1999-09-10 2003-04-25 Didier Raoult Oligonucleotides monocatenaires, sondes, amorces et procede de detection des spirochetes
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
DE19962583A1 (de) * 1999-12-23 2001-06-28 Mueller Hermelink Hans Konrad Antikörper gegen Plasmazellen
GB0006398D0 (en) * 2000-03-16 2000-05-03 Novartis Ag Organic compounds
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
AU2001261585B2 (en) 2000-05-12 2006-08-31 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
IL153593A0 (en) 2000-07-03 2003-07-06 Bristol Myers Squibb Co A pharmaceutical composition containing a soluble ctla4 mutant molecule
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
WO2002012325A2 (fr) * 2000-08-04 2002-02-14 Ludwig Institute For Cancer Research Genes suppresseurs
AU2001287040A1 (en) * 2000-09-01 2002-03-13 Biogen, Inc. Methods of designing and producing novel compounds having improved binding affinity for cd154 or other trimeric proteins
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
AU2002241922B2 (en) * 2001-01-17 2007-10-25 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
AU2008200400B2 (en) * 2001-01-17 2012-06-07 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
CZ305380B6 (cs) 2001-05-23 2015-08-26 Bristol-Myers Squibb Company Léčivo pro inhibici rejekce transplantovaných buněk ostrůvků slinivky břišní
EP2075256A2 (fr) 2002-01-14 2009-07-01 William Herman Ligands ciblés
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
EP1517921B1 (fr) * 2002-06-28 2006-06-07 Domantis Limited Ligands a specificite double et avec une demi-vie augmentee
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
HUE026688T2 (en) 2004-12-28 2016-07-28 Univ Di Genova Monoclonal antibody to NKG2A
CA2609269C (fr) 2005-05-26 2014-08-05 Seattle Genetics, Inc. Anticorps anti-cd40 humanises et procedes d'utilisation
PT1912675E (pt) * 2005-07-25 2014-05-09 Emergent Product Dev Seattle Moléculas de ligaçao especificas para cd37 e especificas para cd20
EP4001409A1 (fr) 2006-03-31 2022-05-25 Chugai Seiyaku Kabushiki Kaisha Procédés pour le contrôle de la pharmacocinétique sanguine d'anticorps
SI2047863T1 (sl) 2006-06-08 2013-11-29 Chugai Seiyaku Kabushiki Kaisha Sredstvo za preprečevanje ali zdravljenje vnetne bolezni
WO2007146968A2 (fr) * 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Protéines de liaison monocaténaires polyvalentes dotées d'une fonction d'effecteur
KR101513498B1 (ko) * 2006-06-30 2015-04-21 노보 노르디스크 에이/에스 항―ｎｋｇ2ａ 항체 및 이들의 용도
KR20090071652A (ko) 2006-10-20 2009-07-01 바이오겐 아이덱 엠에이 인코포레이티드 가용성 림프독소-베타-수용체를 이용한 탈수초성 장애의 치료
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
EP2436696B8 (fr) * 2007-01-05 2017-12-13 University of Zurich Anticorps anti-amyloide et son utilisation
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
CA2978687C (fr) 2007-09-26 2020-02-18 Chugai Seiyaku Kabushiki Kaisha Region constante d'anticorps modifie
US20090123946A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Immunoassays and kits for the detection of ngal
US20090124022A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
US8846036B2 (en) * 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
CN104162155A (zh) 2007-12-05 2014-11-26 中外制药株式会社 搔痒症治疗药
AU2009207644A1 (en) * 2008-01-24 2009-07-30 Novo Nordisk A/S Humanized anti-human NKG2A monoclonal antibody
CN102099377A (zh) * 2008-04-11 2011-06-15 新兴产品开发西雅图有限公司 Cd37免疫治疗剂及其与双功能化学治疗剂的联合
LT2708559T (lt) 2008-04-11 2018-06-11 Chugai Seiyaku Kabushiki Kaisha Antigeną surišanti molekulė, galinti pakartotinai prisijungti prie dviejų ar daugiau antigeno molekulių
PL2305300T3 (pl) * 2008-07-10 2016-09-30 Kompozycja farmaceutyczna do leczenia i zapobiegania nowotworowi
EP2352758A2 (fr) * 2008-09-26 2011-08-10 Wyeth LLC Conception d'une banque d'anticorps simple chaîne
DK2367849T3 (en) 2008-12-05 2018-01-22 Als Therapy Development Inst METHOD OF TREATING NEURODEGENERATIVE DISEASES
KR20160062207A (ko) * 2008-12-05 2016-06-01 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
JP5139517B2 (ja) * 2008-12-05 2013-02-06 中外製薬株式会社 抗ｎｒ１０抗体、およびその利用
JP2010210772A (ja) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
WO2010107109A1 (fr) 2009-03-19 2010-09-23 中外製薬株式会社 Variant d'une région constante d'anticorps
SG190727A1 (en) 2010-11-30 2013-07-31 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
HUE053545T2 (hu) 2011-05-17 2021-07-28 Univ Rockefeller Humán immundeficiencia vírus semlegesítõ antitestek és eljárások alkalmazásukra
BR112013032217B1 (pt) 2011-06-17 2021-01-19 Novo Nordisk A/S uso de um anticorpo anti-nkg2a
WO2013012733A1 (fr) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Régions fc hétérodimères, molécules de liaison les comprenant, et méthodes associées
SMT202000091T1 (it) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
MX390570B (es) 2015-04-14 2025-03-20 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
PL3284480T3 (pl) 2015-04-14 2025-11-12 Chugai Seiyaku Kabushiki Kaisha Kompozycja farmaceutyczna do zapobiegania i/lub leczenia atopowego zapalenia skóry zawierająca jako składnik czynny antagonistę il-31
WO2017053469A2 (fr) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Polypeptides de liaison à cd3
EP3565596A4 (fr) * 2017-01-05 2020-12-16 Brown University Procédés et compositions se rapportant à des réactifs de type anticorps anti-chi3li
AU2018321335B2 (en) 2017-08-22 2025-08-14 Biogen Ma Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
US10766968B2 (en) 2017-08-23 2020-09-08 Brown University Methods and compositions relating to anti-CHI3L1 antibody reagents to treat cancer
CN108484761B (zh) * 2018-03-10 2021-04-30 吉林大学 一种特异性识别并诱导Aβ42的寡聚体及原纤维解聚的单链抗体、单链抗体基因及其应用
CN110950953B (zh) * 2018-09-26 2022-05-13 福州拓新天成生物科技有限公司 抗b7-h3的单克隆抗体及其在细胞治疗中的应用
KR102142499B1 (ko) * 2019-09-11 2020-08-10 재단법인 오송첨단의료산업진흥재단 Ykl-40 표적 인간 단일클론항체
CA3156713A1 (fr) 2019-11-20 2021-05-27 Daisuke Kameoka Preparation pharmaceutique comprenant un anticorps
WO2025117849A1 (fr) 2023-11-28 2025-06-05 Eledon Pharmaceuticals, Inc. Méthodes et compositions pour la prévention du rejet de greffe
WO2025235683A1 (fr) 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Procédés et compositions pour la prévention du rejet de greffe

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0555880A2 (fr) * 1992-02-14 1993-08-18 Bristol-Myers Squibb Company Récepteur CD40CR et ses ligands
WO1995006480A1 (fr) * 1993-09-02 1995-03-09 Trustees Of Dartmouth College Procedes de suppression prolongee de l'immunite humorale
WO1995006666A1 (fr) * 1993-09-02 1995-03-09 Trustees Of Dartmouth College Anticorps anti-gp39 et leurs utilisations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0555880A2 (fr) * 1992-02-14 1993-08-18 Bristol-Myers Squibb Company Récepteur CD40CR et ses ligands
WO1995006480A1 (fr) * 1993-09-02 1995-03-09 Trustees Of Dartmouth College Procedes de suppression prolongee de l'immunite humorale
WO1995006666A1 (fr) * 1993-09-02 1995-03-09 Trustees Of Dartmouth College Anticorps anti-gp39 et leurs utilisations

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A. ARUFFO ET AL.: "The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome.", CELL, vol. 72, 29 January 1993 (1993-01-29), CAMBRIDGE, MA, USA, pages 291 - 300, XP002007297 *
D. HOLLENBAUGH ET AL.: "Expression of functional CD40 by vascular endothelial cells.", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 182, no. 1, 1 July 1995 (1995-07-01), NEW YORK, NY, USA, pages 33 - 40, XP000574867 *
J. BAJORATH ET AL.: "Identification of residues on CD40 and its ligand which are critical for the receptor-ligand interaction.", BIOCHEMISTRY, vol. 34, no. 6, 14 February 1995 (1995-02-14), WASHINGTON, DC, USA, pages 1833 - 1844, XP002007296 *
L. RIECHMANN ET AL.: "Reshaping human antibodies for therapy.", NATURE, vol. 332, 24 March 1988 (1988-03-24), LONDON, GB, pages 323 - 327, XP002007298 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US9399680B2 (en) 2007-12-05 2016-07-26 Chugai Seiyaku Kabushiki Kaisha Nucleic acids encoding anti-NR10 antibodies
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant

Also Published As

Publication number Publication date
EP1728864B1 (fr) 2012-08-01
JPH10513348A (ja) 1998-12-22
EP1728864A1 (fr) 2006-12-06
AU4966996A (en) 1996-08-14
IL116882A0 (en) 1996-05-14
PL182868B1 (pl) 2002-03-29
FI973120A0 (fi) 1997-07-25
MX9705610A (es) 1997-10-31
FI973120A7 (fi) 1997-07-25
ES2391101T3 (es) 2012-11-21
NZ303375A (en) 2000-01-28
HUP9802401A3 (en) 2003-03-28
US5876950A (en) 1999-03-02
IL116882A (en) 2001-09-13
AU692074B2 (en) 1998-05-28
CZ233997A3 (en) 1997-11-12
PL323565A1 (en) 1998-04-14
NO973447L (no) 1997-09-26
CA2210419A1 (fr) 1996-08-01
HUP9802401A2 (hu) 1999-01-28
WO1996023071A2 (fr) 1996-08-01
NO973447D0 (no) 1997-07-25
EP0807175A2 (fr) 1997-11-19

Similar Documents

Publication Publication Date Title
WO1996023071A3 (fr) ANTICORPS MONOCLONAUX SPECIFIQUES DE DIFFERENTS EPITOPES DE gp39 HUMAINE ET PROCEDES CONCERNANT LEUR UTILISATION A DES FINS DE DIAGNOSTIC ET DE THERAPIE
RU2207878C2 (ru) "очеловеченные" антитела против gp39 человека, композиции, содержащие эти антитела, и их терапевтическое использование
US6572857B1 (en) Anti-CD6 monoclonal antibodies and their uses
ATE132197T1 (de) Monoklonale antikörper
KR960706560A (ko) 인화 항체 및 이것의 사용 방법(humanized antibodies and uses thereof)
PT712307E (pt) Metodos para controlo da populacao de celulas b
RU96115107A (ru) "очеловеченные" антитела и их использование
KR102866306B1 (ko) 신경 성장 인자에 대한 단일 클론 항체, 및 이의 코딩 유전자 및 용도
EP1798243A3 (fr) Anticorps recombinants associés aux gangliosides et leur utilisation dans le diagnostic et le traitement des tumeurs
KR927003816A (ko) Cd3에 대한 항체
RU2007133608A (ru) Моноклональные антитела против интерферона-альфа и способы применения
KR960704575A (ko) 항원-특이적 t 세포의 내성을 유도하는 방법(methods for inducing antigen-specific tcell tolerance)
JP2022058881A (ja) 多発性骨髄腫におけるｍタンパク質反応の臨床評価
RU95118411A (ru) Гибридная клеточная линия (варианты), препарат антител (варианты), способ диагностики рассеянного склероза у человека (варианты) способ лечения человека, полипептид
CA2121498A1 (fr) Peptides «recombitopes»
DE69535562D1 (de) Rekombinantpeptide hergeleitet vom mc3 antikörper gegen ba46, verfahren zu deren verwendung und verfahren zur humanisierung von antikörperpeptiden
Radl Animal model of human disease. Benign monoclonal gammopathy (idiopathic paraproteinemia)
DE68927635T2 (de) Igm-antikörper gegen protamin
JPH10509948A (ja) Ｔ細胞受容体ペプチドに対するヒト抗体およびそれらの調製方法
WO1994011508A3 (fr) Polypeptides presentant une specificite par rapport aux neoplasies, kit et procedes diagnostiques, therapeutiques et de vaccination
WO1994028023A1 (fr) Proteine de membranes cellulaires exprimee par les thymocites du cortex humain, et son emploi
Natvig et al. Partial amino acid sequence analysis and variable subgroup determination (VH and VL) of a monoclonal rheumatoid factor derived from a rheumatoid arthritis patient
CN117903313B (zh) 一种抗iars抗体及其应用
Kirschning et al. Primary structure of the antigen-binding domains of a human oligodendrocyte-reactive IgM monoclonal antibody derived from a patient with multiple sclerosis
Tagawa et al. The 301 to 314 amino acid residue of β-tubulin is not a target epitope for serum IgM antibodies in chronic inflammatory demyelinating polyneuropathy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CZ FI HU JP MX NO NZ PL US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1/27-27/27,DRAWINGS,REPLACED BY NEW PAGES BEARING THE SAME NUMBER;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

ENP Entry into the national phase

Ref country code: US

Ref document number: 1997 860052

Date of ref document: 19970617

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 303375

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2210419

Country of ref document: CA

Ref country code: CA

Ref document number: 2210419

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PV1997-2339

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/1997/005610

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 973120

Country of ref document: FI

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1996 523029

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996906207

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1997-2339

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1996906207

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV1997-2339

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1996906207

Country of ref document: EP